查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1474877

抗體藥物複合體市場規模、佔有率、趨勢分析報告：按應用、按技術、按產品、按目標、按地區、細分市場預測，2024-2030

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

抗體藥物偶聯物市場成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年，全球抗體藥物偶聯物市場規模將達到240.1億美元，預測期內複合年成長率為9.2%。

強大的研發線產品和主要企業的策略舉措的出現預計將在預測期內推動市場成長。

ADC Therapeutics、Seagen.Inc.、武田藥品工業株式會社、F. Hoffmann-La Roche Ltd.、阿斯特捷利康、第一三共等公司正在合作開發和商業化該產品。例如，2022年2月，Mersana Therapeutics與強生公司子公司楊森製藥公司合作，研發新型ADC來治療各種癌症。根據協議，楊森製藥公司將向 Mersana Therapeutics 支付 4,000 萬美元的預付款，並可能為新 ADC 開發的里程碑支付超過 10 億美元。

製藥公司對新型抗體藥物偶聯物開發的廣泛研究和不斷增加的資金籌措預計將推動市場成長。例如，2021 年 4 月，兩家新新興企業Adcendo 和 Adcentrx 籌集了約 1.12 億美元的資金，用於開發具有癌症治療新方法的 ADC。 Adcendo 已籌集 5,100 萬美元用於開發一種針對內吞受體（充當藥物傳輸載體）的新型 ADC。 Adcentrx 已為其 ADC 研究計畫籌集了 5,000 萬美元。

此外，2022 年 3 月，ImmunoGen, Inc. 宣布已向美國FDA 提交了 mirvetuximab soravtansine 單藥治療卵巢癌患者的生技藥品許可申請 (BLA)。該製劑由 α 連接抗體、可裂解接頭和作為有效負載殺死目標癌細胞的美登木素生物鹼 DM4 組成。

與單株抗體療法和化療等替代傳統療法相比，ADC 的治療高成本，因此嚴格的 ADC 報銷政策可能會抑制市場成長。這種治療的高昂費用預計會阻礙報銷。例如，2020年2月，愛爾蘭國家藥物經濟學中心對羅氏Kadcyla （曲妥珠單抗emtansine）給予報銷負面審查，理由是其缺乏成本效益。

老年人口的增加和多發性骨髓瘤 (MM) 等疾病盛行率的增加預計將推動預測期內對 ADC 的需求並推動市場成長。多發性骨髓瘤 (MM) 是一種人口老化疾病，2021 年診斷出近 30,000 例新發 MM 病例。被診斷為多發性骨髓瘤的患者的中位年齡為 70 歲。因此，採用新型 ADC 進行多發性骨髓瘤治療預計將促進市場成長。例如，2020年8月，FDA核准GlaxoSmithKline Plc的BLENREP作為單一療法治療復發或難治性多發性骨髓瘤。 Brenrep 是第一個核准用於治療多發性骨髓瘤的抗 BCMA 療法。

抗體藥物偶聯物市場報告亮點

  • 由於乳癌的高盛行率以及多種用於乳癌治療的 ADC 產品的可用性，乳癌在 2023 年以 47.76% 的最大銷售佔有率佔據市場主導地位。
  • 由於商業ADC產品中擴大採用可裂解連接器技術，以及使用可裂解連接器相對於其他連接器技術的優勢，可裂解連接器細分市場將在2023年成長72.43%，佔收益佔有率。
  • 從連接器技術類型來看，市場上有許多高效的連接器用於將有效負載傳遞到目標位點，例如SMCC、SPP、MCC、胜肽、CL2A、MC（馬來醯亞胺己醯基）等。
  • 由於輝瑞公司（Pfizer, Inc.）、吉利德生命科學公司（Gilead Life Sciences, Inc.）和希根公司（Seagen, Inc.）等主要製藥公司的存在，以及開發新ADC 的策略努力，2023 年北美將收益佔有率52.54% 的收入市場佔有率被壟斷了。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場趨勢及展望
  • 市場動態
    • 存在強大的產品平臺
    • 人口老化加劇
    • 癌症發生率和盛行率增加
  • 市場限制因素分析
    • ADC 的高製造成本與下游加工挑戰
    • ADC 分析挑戰
    • 嚴格的 ADC 報銷政策
  • 營商環境分析
    • 依因素（政治/法律、經濟/技術）進行 SWOT 分析
    • 波特五力分析
    • COVID-19 影響分析
  • ADC開發平台定性分析
    • Creative Biolabs
    • Mersana Therapeutics
    • Heidelberg Pharma
    • Synaffix BV
    • NBE Therapeutics
    • VERAXA
    • Tubulis Gmbh
    • Byondis Platform
    • Immunogen, Inc.
    • RemeGen
    • Wuxi Biologics
    • Merck & Co., Inc.
    • Ambrx

第4章抗體藥物偶聯物市場：按應用細分分析，2018-2030（百萬美元）

  • 抗體藥物偶聯物市場：應用變化分析
  • 血癌
  • 乳癌
  • 尿路上皮癌/膀胱癌
  • 其他

第5章抗體藥物偶聯物市場：按產品細分分析，2018-2030（百萬美元）

  • 抗體藥物偶聯物市場：產品波動分析
  • 門頭
  • 恩赫圖
  • ADCETRIS
  • 帕多切夫
  • 波利維
  • 其他

第6章抗體藥物偶聯物市場：按目標細分分析，2018-2030（百萬美元）

  • 抗體藥物偶聯物市場：標靶變異分析
  • HER2
  • CD22
  • CD30
  • 其他

第 7 章抗體藥物偶聯物市場：按技術細分分析，2018-2030 年（百萬美元）

  • 抗體藥物偶聯物市場：技術變化分析
  • 按類型
  • 連接器技術
  • 有效載荷技術

第8章抗體藥物偶聯物市場：區域分析，2018-2030（百萬美元）

  • 2022年及2030年抗體藥物偶聯物市場佔有率（按地區）
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第9章 競爭格局

  • 公司分類
  • 策略規劃
    • 新產品發布
    • 合夥
    • 獲得
    • 合作
    • 資金籌措
  • 2023年主要企業市場佔有率分析
  • 公司簡介
    • Takeda Pharmaceutical Company Limited
    • F.Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Astrazeneca
    • Gilead Sciences, Inc.
    • Astellas Pharma Inc.
    • Seagen, Inc.
    • Daiichi Sankyo Company, Limited
    • Glaxosmithkline Plc.
    • Adc Therapeutics Sa
    • Synaffix Bv

第10章 Kol建議/結論

Product Code: GVR-2-68038-741-4

Antibody Drug Conjugates Market Growth & Trends:

The global antibody drug conjugates market size is expected to reach USD 24.01 billion by 2030, registering a CAGR of 9.2% during the forecast period, according to a new report by Grand View Research, Inc. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive the market growth during the forecast period.

Key players such as ADC Therapeutics, Seagen. Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, Daiichi Sankyo, and others are collaborating to develop and commercialize products. For instance, in February 2022, Mersana Therapeutics, partnered with Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson Inc., for the research and development of novel ADCs to treat various cancers. Under this agreement, Janssen will pay Mersana Therapeutics USD 40.0 million upfront and potentially more than USD 1.0 billion in milestone-based payments for the development of new ADCs.

Extensive research and rising funding for the development of novel antibody-drug conjugates by pharmaceutical companies is projected to drive market growth. For instance, in April 2021, Adcendo and Adcentrx, two new startups raised funding of around USD 112.0 million for the development of ADCs with their new approach to the treatment of cancer. Adcendo raised USD 51.0 million for the development of new ADCs that target endocytic receptors, which play the role of the drug delivery body. Adcentrx raised USD 50.0 million for its ADC research programs.

Additionally, in March 2022, ImmunoGen, Inc. announced the submission of biological license application (BLA) to the U.S. FDA for mirvetuximab soravtansine used as monotherapy in patients with ovarian cancer. It comprises alpha-binding antibody, cleavable linker, and the maytansinoid DM4 as payload to kill the targeted cancer cells.

Stringent reimbursement policies for ADCs may restrain the market growth due to the high cost associated with the treatment of ADCs as compared to the alternative conventional treatments such as monoclonal antibodies therapy & chemotherapy. This higher cost of treatment is expected to impede reimbursement coverage. For instance, in February 2020, National Centre for Pharmaco economics, Ireland, gave a negative review for Roche's Kadcyla (trastuzumab emtansine) for reimbursement consideration due to its low cost-effectiveness.

The rising geriatric population coupled with the increasing prevalence of the diseases such as multiple myeloma (MM) is expected to drive demand for ADCs, thereby driving the market growth during the forecast period. Multiple myeloma (MM) is a disease of the aging population, and nearly 30,000 new cases of MM were diagnosed in 2021. The median age of diagnosed patients with multiple myeloma is 70 years. Thus, the introduction of new ADCs for the treatment of multiple myeloma is expected to boost market growth. For instance, in August 2020, the FDA approved BLENREP by GlaxoSmithKline as a monotherapy to treat relapsed or refractory multiple myeloma. Blenrep was the first anti-BCMA therapy approved for the treatment of multiple myeloma.

Antibody Drug Conjugates Market Report Highlights:

  • Breast cancer dominated the market for the largest revenue share of 47.76% in 2023, owing to the high prevalence of breast cancer and the availability of multiple ADC products for treating the breast cancer
  • Cleavable linker segment accounted for largest revenue share of 72.43% in 2023 due to the rising adoption of cleavable linker technology in commercial ADC products and the advantages associated with the use of cleavable linkers over other linker technology
  • Based on linker Technology Type, others segment dominated the market due to presence of a large number of highly effective linkers in market such as SMCC, SPP, MCC, maleimide tetrapeptide, CL2A, and MC (Maleimidocaproyl) used to deliver payloads to their target sites.
  • North America dominated the market in terms of revenue share of 52.54% in 2023 due to the presence of key pharmaceutical companies such as Pfizer, Inc, Gilead Life Sciences, Inc., and Seagen, Inc. and their strategic initiatives for the development of new ADCs

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1 Market Segmentation And Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Application Segment
      • 1.1.1.2 Technology Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 GVR' s Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Technology And Application Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends And Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Presence Of Strong Product Pipeline
    • 3.4.2. Growing Geriatric Population Base
    • 3.4.3. Increasing Incidence And Prevalence Of Cancer
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Manufacturing Cost And Downstream Processing Challenges For ADCs
    • 3.5.2. Analytical Challenges For ADCs
    • 3.5.3. Stringent Reimbursement Policies For ADCs
  • 3.6. Business Environment Analysis
    • 3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. Covid-19 Impact Analysis
  • 3.7. Qualitative Analysis For ADC Development Platforms
    • 3.7.1. Creative Biolabs
    • 3.7.2. Mersana Therapeutics
    • 3.7.3. Heidelberg Pharma
    • 3.7.4. Synaffix BV
    • 3.7.5. NBE Therapeutics
    • 3.7.6. VERAXA
    • 3.7.7. Tubulis Gmbh
    • 3.7.8. Byondis Platform
    • 3.7.9. Immunogen, Inc.
    • 3.7.10. RemeGen
    • 3.7.11. Wuxi Biologics
    • 3.7.12. Merck & Co., Inc.
    • 3.7.13. Ambrx

Chapter 4. Antibody Drug Conjugates Market: Segment Analysis By Application, 2018 - 2030 (USD Million)

  • 4.1. Antibody Drug Conjugates Market: Application Movement Analysis
  • 4.2. Blood Cancer
    • 4.2.1. Blood Cancer Market, 2018 - 2030 (USD Million)
    • 4.2.2. Leukemia
      • 4.2.2.1. Leukemia Market, 2018 - 2030 (USD Million)
    • 4.2.3. Multiple Myeloma
      • 4.2.3.1. Multiple Myeloma Market, 2018 - 2030 (USD Million)
    • 4.2.4. Lymphoma
      • 4.2.4.1. Lymphoma Market, 2018 - 2030 (USD Million)
  • 4.3. Breast Cancer
  • 4.4. Urothelial/Bladder Cancer
    • 4.4.1. Urothelial/Bladder Cancer Market, 2018 - 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Antibody Drug Conjugates Market: Segment Analysis By Product, 2018 - 2030 (USD Million)

  • 5.1. Antibody Drug Conjugates Market: Product Movement Analysis
  • 5.2. Kadcyla
    • 5.2.1. Kadcyla Market, 2018 - 2030 (USD Million)
  • 5.3. Enhertu
    • 5.3.1. Enhertu Market, 2018 - 2030 (USD Million)
  • 5.4. Adcetris
    • 5.4.1. Adcetris Market, 2018 - 2030 (USD Million)
  • 5.5. Padcev
    • 5.5.1. Padcev Market, 2018 - 2030 (USD Million)
  • 5.6. Polivy
    • 5.6.1. Polivy Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Antibody Drug Conjugates Market: Segment Analysis By Target, 2018 - 2030 (USD Million)

  • 6.1. Antibody Drug Conjugates Market: Target Movement Analysis
  • 6.2. HER2
    • 6.2.1. HER2 Market, 2018 - 2030 (USD Million)
  • 6.3. CD22
    • 6.3.1. CD22 Market, 2018 - 2030 (USD Million)
  • 6.4. CD30
    • 6.4.1. CD30 Market, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others market, 2018 - 2030 (USD Million)

Chapter 7. Antibody Drug Conjugates Market: Segment Analysis By Technology, 2018 - 2030 (USD Million)

  • 7.1. Antibody Drug Conjugates Market: Technology Movement Analysis
  • 7.2. By Type
    • 7.2.1. Cleavable Linker
      • 7.2.1.1. Cleavable Linker Market, 2018 - 2030 (USD Million)
    • 7.2.2. Non-Cleavable Linker
      • 7.2.2.1. Non-Cleavable Linker Market, 2018 - 2030 (USD Million)
    • 7.2.3. Linkerless
      • 7.2.3.1. Linkerless Market, 2018 - 2030 (USD Million)
  • 7.3. By Linker Technology
    • 7.3.1. Vc (Valine-Citrulline)
      • 7.3.1.1. Vc Market, 2018 - 2030 (USD Million)
    • 7.3.2. Sulfo-SPDB
      • 7.3.2.1. Sulfo-SPDB Market, 2018 - 2030 (USD Million)
    • 7.3.3. VA (Valine Alanine)
      • 7.3.3.1. VA (Valine Alanine) Market, 2018 - 2030 (USD Million)
    • 7.3.4. Hydrazone
      • 7.3.4.1. Hydrazone Market, 2018 - 2030 (USD Million)
    • 7.3.5. Others
      • 7.3.5.1. Others Market, 2018 - 2030 (USD Million)
  • 7.4. By Payload Technology
    • 7.4.1. MMAE
      • 7.4.1.1. MMAE Market, 2018 - 2030 (USD Million)
    • 7.4.2. MMAF
      • 7.4.2.1. MMAF Market, 2018 - 2030 (USD Million)
    • 7.4.3. Dm4
      • 7.4.3.1. Dm4 Market, 2018 - 2030 (USD Million)
    • 7.4.4. Camptothecin
      • 7.4.4.1. Camptothecin Market, 2018 - 2030 (USD Million)
    • 7.4.5. Others
      • 7.4.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Antibody Drug Conjugates Market: Regional Analysis, 2018 - 2030 (USD Million)

  • 8.1. Antibody Drug Conjugates Market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. Swot Analysis
    • 8.2.2. North America Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.2.3. U.S.
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. U.S. Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.2.4. Canada
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
      • 8.2.4.6. Canada Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Swot Analysis
    • 8.3.2. Europe Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. Germany Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.4. UK
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. UK Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.5. France
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. France Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.6. Italy
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Italy Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.7. Spain
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Spain Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.8. Denmark
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Denmark Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.9. Sweden
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Sweden Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.10. Norway
      • 8.3.10.1. Key Country Dynamics
      • 8.3.10.2. Target Disease Prevalence
      • 8.3.10.3. Competitive Scenario
      • 8.3.10.4. Regulatory Framework
      • 8.3.10.5. Reimbursement Scenario
      • 8.3.10.6. Norway Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Swot Analysis
    • 8.4.2. Asia Pacific Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. Japan Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.4.4. China
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. China Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.4.5. India
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. India Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. South Korea Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.4.7. Australia
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Australia Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.4.8. Thailand
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Target Disease Prevalence
      • 8.4.8.3. Competitive Scenario
      • 8.4.8.4. Regulatory Framework
      • 8.4.8.5. Reimbursement Scenario
      • 8.4.8.6. Thailand Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Swot Analysis
    • 8.5.2. Latin America Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.5.3. Brazil
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Brazil Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Reimbursement Scenario
      • 8.5.4.6. Mexico Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.5.5. Argentina
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Competitive Scenario
      • 8.5.5.4. Regulatory Framework
      • 8.5.5.5. Reimbursement Scenario
      • 8.5.5.6. Argentina Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
  • 8.8. Middle East and Africa (MEA)
    • 8.8.1. Swot Analysis
    • 8.8.2. MEA Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.8.3. South Africa
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Competitive Scenario
      • 8.8.3.4. Regulatory Framework
      • 8.8.3.5. Reimbursement Scenario
      • 8.8.3.6. South Africa Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.8.4. Saudi Arabia
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Competitive Scenario
      • 8.8.4.4. Regulatory Framework
      • 8.8.4.5. Reimbursement Scenario
      • 8.8.4.6. Saudi Arabia Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.8.5. UAE
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Competitive Scenario
      • 8.8.5.4. Regulatory Framework
      • 8.8.5.5. Reimbursement Scenario
      • 8.8.5.6. UAE Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.8.6. Kuwait
      • 8.8.6.1. Key Country Dynamics
      • 8.8.6.2. Target Disease Prevalence
      • 8.8.6.3. Competitive Scenario
      • 8.8.6.4. Regulatory Framework
      • 8.8.6.5. Reimbursement Scenario
      • 8.8.6.6. Kuwait Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1 Company Categorization
  • 9.2 Strategy Mapping
    • 9.2.1 New Product Launch
    • 9.2.2 Partnerships
    • 9.2.3 Acquisition
    • 9.2.4 Collaboration
    • 9.2.5 Funding
  • 9.3 Key Company Market Share Analysis, 2023
  • 9.4 Company Profiles
    • 9.4.1 Takeda Pharmaceutical Company Limited
      • 9.4.1.1 Company Overview
      • 9.4.1.2 Financial Performance
      • 9.4.1.3 Product Benchmarking
      • 9.4.1.4 Strategic Initiatives
    • 9.4.2 F.Hoffmann-La Roche Ltd.
      • 9.4.2.1 Company Overview
      • 9.4.2.2 Financial Performance
      • 9.4.2.3 Product Benchmarking
      • 9.4.2.4 Strategic Initiatives
    • 9.4.3 Pfizer, Inc.
      • 9.4.3.1 Company Overview
      • 9.4.3.2 Financial Performance
      • 9.4.3.3 Product Benchmarking
      • 9.4.3.4 Strategic Initiatives
    • 9.4.4 Astrazeneca
      • 9.4.4.1 Company Overview
      • 9.4.4.2 Product Benchmarking
      • 9.4.4.3 Strategic Initiatives
    • 9.4.5 Gilead Sciences, Inc.
      • 9.4.5.1 Company Overview
      • 9.4.5.2 Financial Performance
      • 9.4.5.3 Product Benchmarking
      • 9.4.5.4 Strategic Initiatives
    • 9.4.6 Astellas Pharma Inc.
      • 9.4.6.1 Company Overview
      • 9.4.6.2 Financial Performance
      • 9.4.6.3 Product Benchmarking
      • 9.4.6.4 Strategic Initiatives
    • 9.4.7 Seagen, Inc.
      • 9.4.7.1 Company Overview
      • 9.4.7.2 Financial Performance
      • 9.4.7.3 Product Benchmarking
      • 9.4.7.4 Strategic Initiatives
    • 9.4.8 Daiichi Sankyo Company, Limited
      • 9.4.8.1 Company Overview
      • 9.4.8.2 Financial Performance
      • 9.4.8.3 Product Benchmarking
      • 9.4.8.4 Strategic Initiatives
    • 9.4.9 Glaxosmithkline Plc.
      • 9.4.9.1 Company Overview
      • 9.4.9.2 Financial Performance
      • 9.4.9.3 Product Benchmarking
      • 9.4.9.4 Strategic Initiatives
    • 9.4.10 Adc Therapeutics Sa
      • 9.4.10.1 Company Overview
      • 9.4.10.2 Financial Performance
      • 9.4.10.3 Product Benchmarking
      • 9.4.10.4 Strategic Initiatives
    • 9.4.11 Synaffix Bv
      • 9.4.11.1 Company Overview
      • 9.4.11.2 Financial Performance
      • 9.4.11.3 Product Benchmarking
      • 9.4.11.4 Strategic Initiatives

Chapter 10. Kol Recommendations/ Conclusion

List of Tables

  • TABLE 1 List of abbreviation
  • TABLE 2 List of secondary sources
  • TABLE 3 Global antibody-drug conjugates market estimates and forecasts, by region, 2018 - 2030 (USD Million)
  • TABLE 4 Global antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 5 Global antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 6 Global antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 7 Global antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 8 Global antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 9 Global antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 10 North America antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 11 North America antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 12 North America antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 13 North America antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 14 North America antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 15 North America antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 16 North America antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 17 U.S. antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 18 U.S. antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 19 U.S. antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 20 U.S. antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 21 U.S. antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 22 U.S. antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 23 Canada antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 24 Canada antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 25 Canada antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 26 Canada antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 27 Canada antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 28 Canada antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 29 Europe antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 30 Europe antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 31 Europe antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 32 Europe antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 33 Europe antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 34 Europe antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 35 Europe antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 36 Europe antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 37 UK antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 38 UK antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 39 UK antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 40 UK antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 41 UK antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 42 UK antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 43 Germany antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 44 Germany antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 45 Germany antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 46 Germany antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 47 Germany antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 48 Germany antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 49 France antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 50 France antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 51 France antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 52 France antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 53 France antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 54 France antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 55 Italy antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 56 Italy antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 57 Italy antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 58 Italy antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 59 Italy antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 60 Italy antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 61 Spain antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 62 Spain antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 63 Spain antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 64 Spain antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 65 Spain antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 66 Spain antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 67 Denmark antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 68 Denmark antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 69 Denmark antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 70 Denmark antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 71 Denmark antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 72 Denmark antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 73 Sweden antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 74 Sweden antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 75 Sweden antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 76 Sweden antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 77 Sweden antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 78 Sweden antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 79 Norway antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 80 Norway antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 81 Norway antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 82 Norway antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 83 Norway antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 84 Norway antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 85 Asia Pacific antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 86 Asia Pacific antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 87 Asia Pacific antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 88 Asia Pacific antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 89 Asia Pacific antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 90 Asia Pacific antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 91 Japan antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 92 Japan antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 93 Japan antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 94 Japan antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 95 Japan antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 96 Japan antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 97 China antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 98 China antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 99 China antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 100 China antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 101 China antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 102 China antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 103 India antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 104 India antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 105 India antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 106 India antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 107 India antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 108 India antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 109 Australia antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 110 Australia antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 111 Australia antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 112 Australia antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 113 Australia antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 114 Australia antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 115 South Korea antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 116 South Korea antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 117 South Korea antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 118 South Korea antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 119 South Korea antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 120 South Korea antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 121 Thailand antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 122 Thailand antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 123 Thailand antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 124 Thailand antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 125 Thailand antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 126 Thailand antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 127 Latin America antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 128 Latin America antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 129 Latin America antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 130 Latin America antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 131 Latin America antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 132 Latin America antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 133 Brazil antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 134 Brazil antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 135 Brazil antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 136 Brazil antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 137 Brazil antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 138 Brazil antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 139 Mexico antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 140 Mexico antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 141 Mexico antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 142 Mexico antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 143 Mexico antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 144 Mexico antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 145 Argentina antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 146 Argentina antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 147 Argentina antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 148 Argentina antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 149 Argentina antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 150 Argentina antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 151 MEA antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 152 MEA antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 153 MEA antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 154 MEA antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 155 MEA antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 156 MEA antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 157 South Africa antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 158 South Africa antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 159 South Africa antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 160 South Africa antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 161 South Africa antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 162 South Africa antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 163 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 164 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 165 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 166 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 167 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 168 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 169 UAE antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 170 UAE antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 171 UAE antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 172 UAE antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 173 UAE antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 174 UAE antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 175 Kuwait antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 176 Kuwait antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 177 Kuwait antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 178 Kuwait antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 179 Kuwait antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 180 Kuwait antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 181 List of key distributors
  • TABLE 182 List of key emerging companies/technology disruptors/innovators

List of Figures

  • FIG. 1 Antibody-drug conjugates market segmentation
  • FIG. 2 Market research process
  • FIG. 3 Data triangulation techniques
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value-chain-based sizing & forecasting
  • FIG. 7 QFD modeling for market share assessment
  • FIG. 8 Market formulation & validation
  • FIG. 9 Antibody-drug conjugates market snapshot
  • FIG. 10 Antibody-drug conjugates market driver impact
  • FIG. 11 Global population by age group, 2016, 2022, & 2027
  • FIG. 12 Global cancer cases projection,2020 - 2030 (Number of new registered cases)
  • FIG. 13 Antibody-drug conjugates market restraint impact
  • FIG. 14 Penetration and growth prospect mapping
  • FIG. 15 SWOT analysis, by factor (political & legal economic and technological)
  • FIG. 16 Porter's five forces analysis
  • FIG. 17 Antibody-drug conjugates market: Application outlook and key takeaways
  • FIG. 18 Antibody-drug conjugates market: Application movement analysis
  • FIG. 19 Blood cancer market estimates and forecasts, 2018 - 2030
  • FIG. 20 Leukemia market estimates and forecasts, 2018 - 2030
  • FIG. 21 Multiple Myeloma market estimates and forecasts, 2018 - 2030
  • FIG. 22 Lymphoma market estimates and forecasts, 2018 - 2030
  • FIG. 23 Breast cancer market estimates and forecasts, 2018 - 2030
  • FIG. 24 Urothelial cancer market estimates and forecasts, 2018 - 2030
  • FIG. 25 Others market estimates and forecasts, 2018 - 2030
  • FIG. 26 Antibody-drug conjugates market: Product outlook and key takeaways
  • FIG. 27 Antibody-drug conjugates market: Product movement analysis
  • FIG. 28 Kadcyla market estimates and forecasts, 2018 - 2030
  • FIG. 29 Enhertu market estimates and forecasts, 2018 - 2030
  • FIG. 30 Adcetris market estimates and forecasts, 2018 - 2030
  • FIG. 31 Padcev market estimates and forecasts, 2018 - 2030
  • FIG. 32 Trodelvy market estimates and forecasts, 2018 - 2030
  • FIG. 33 Polivy market estimates and forecasts, 2018 - 2030
  • FIG. 34 Others market estimates and forecasts, 2018 - 2030
  • FIG. 35 Antibody-drug conjugates market: Target outlook and key takeaways
  • FIG. 36 Antibody-drug conjugates market: Target movement analysis
  • FIG. 37 HER2 market estimates and forecasts, 2018 - 2030
  • FIG. 38 CD22 market estimates and forecasts, 2018 - 2030
  • FIG. 39 CD30 market estimates and forecasts, 2018 - 2030
  • FIG. 40 Others market estimates and forecasts, 2018 - 2030
  • FIG. 41 Antibody-drug conjugates market: Technology outlook and key takeaways
  • FIG. 42 Antibody-drug conjugates market: Technology movement analysis
  • FIG. 43 Cleavable linker market estimates and forecasts, 2018 - 2030
  • FIG. 44 Non-cleavable linker market estimates and forecasts, 2018 - 2030
  • FIG. 45 Linkerless market estimates and forecasts, 2018 - 2030
  • FIG. 46 VC (valine-citrulline) market estimates and forecasts, 2018 - 2030
  • FIG. 47 Sulfo-SPDB market estimates and forecasts, 2018 - 2030
  • FIG. 48 VA (valine alanine) market estimates and forecasts, 2018 - 2030
  • FIG. 49 Hydrazone market estimates and forecasts, 2018 - 2030
  • FIG. 50 Others market estimates and forecasts, 2018 - 2030
  • FIG. 51 MMAE market estimates and forecasts, 2018 - 2030
  • FIG. 52 MMAF market estimates and forecasts, 2018 - 2030
  • FIG. 53 DM4 market estimates and forecasts, 2018 - 2030
  • FIG. 54 Camptothecin market estimates and forecasts, 2018 - 2030
  • FIG. 55 Others market estimates and forecasts, 2018 - 2030
  • FIG. 56 Antibody-drug conjugates market: Regional outlook and key takeaways
  • FIG. 57 Antibody-drug conjugates market: Regional movement analysis
  • FIG. 58 North America SWOT analysis
  • FIG. 59 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 60 U.S. key country dynamics
  • FIG. 61 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 62 Canada key country dynamics
  • FIG. 63 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 64 Europe SWOT analysis
  • FIG. 65 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 66 UK key country dynamics
  • FIG. 67 UK market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 68 Germany key country dynamics
  • FIG. 69 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 70 Italy key country dynamics
  • FIG. 71 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 72 Spain key country dynamics
  • FIG. 73 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 74 Denmark key country dynamics
  • FIG. 75 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 76 Sweden key country dynamics
  • FIG. 77 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 78 Norway key country dynamics
  • FIG. 79 Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 80 France key country dynamics
  • FIG. 81 France market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 82 Asia Pacific SWOT analysis
  • FIG. 83 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 84 Japan key country dynamics
  • FIG. 85 Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 86 China key country dynamics
  • FIG. 87 China market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 88 India key country dynamics
  • FIG. 89 India market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 90 Australia key country dynamics
  • FIG. 91 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 92 South Korea key country dynamics
  • FIG. 93 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 94 Thailand key country dynamics
  • FIG. 95 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 96 Latin America SWOT analysis
  • FIG. 97 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 98 Brazil key country dynamics
  • FIG. 99 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 100 Mexico key country dynamics
  • FIG. 101 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 102 Argentina key country dynamics
  • FIG. 103 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 104 Middle East & Africa SWOT analysis
  • FIG. 105 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 106 South Africa key country dynamics
  • FIG. 107 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 108 Saudi Arabia key country dynamics
  • FIG. 109 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 110 UAE key country dynamics
  • FIG. 111 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 112 Kuwait key country dynamics
  • FIG. 113 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 114 Company market share analysis
  • FIG. 115 Company market position analysis (Revenue US$ mn)
  • FIG. 116 Company market position analysis (Profit Margin)
  • FIG. 117 Competitive dashboard analysis
  • FIG. 118 Regional Network Map